Biopharmaceutical Third-Party Logistics Market Outlook:
Biopharmaceutical Third-Party Logistics Market size was valued at USD 150.28 billion in 2025 and is likely to cross USD 284.76 billion by 2035, expanding at more than 6.6% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of biopharmaceutical third-party logistics is assessed at USD 159.21 billion.
The market growth is fostered due to emerging biopharmaceutical industries with advanced technologies offering immense growth opportunities. The high demand for effective logistics, increasing prevalence of chronic diseases, and rising approval for a wide range of biologics and biosimilars are some key factors boosting global biopharmaceutical third-party logistics market growth. Moreover, the rising manufacturing of biopharmaceuticals has encouraged third-party providers to develop advanced temperature-controlled storage and transportation solutions and services.
The market growth has been surged by the expansion into the biopharmaceuticals sector by logistics companies such as DHL and UPS, and growing adoptions of advanced technologies such as IoT sensors and blockchain, further enhancing supply chain visibility and security. For instance, McKesson Third Party Logistics (3PL) pledges to render comprehensive support to biopharma companies of all sizes, ranging from licensing needs to business planning to monitoring programming. Companies follow stringent norms and complex procedures for the pricing and manufacturing of biological products and biopharmaceuticals as these are derived from living cells and are sensitive as compared to traditional pharmaceutical drugs. According to the U.S. Bureau of Labor Statistics, the Producer Price Index (PPI) of biological products and drug manufacturing reached 254.0 in July 2024.
